Recent Advances in Pediatric Medulloblastoma.

Brain tumors Chemotherapy Pediatric medulloblastoma Radiation therapy

Journal

Current neurology and neuroscience reports
ISSN: 1534-6293
Titre abrégé: Curr Neurol Neurosci Rep
Pays: United States
ID NLM: 100931790

Informations de publication

Date de publication:
09 Nov 2023
Historique:
accepted: 16 10 2023
medline: 9 11 2023
pubmed: 9 11 2023
entrez: 9 11 2023
Statut: aheadofprint

Résumé

Review recent advances in the understanding of pediatric medulloblastoma including etiology, biology, radiology, and management of pediatric medulloblastoma. The classic four subgroups have been reclassified and further subdivided based on new molecular findings. Research is revealing the cell origins of the different subtypes of medulloblastoma. There has been continued personalization of management based on molecular parameters. While many advances have been made in the knowledge base of this most common malignant pediatric brain tumor, there has not yet been translation into more effective therapies to prolong survival in all subgroups with the possible exception of children with group 3 disease. Quality of life remains a major challenge for long-term survivors.

Identifiants

pubmed: 37943476
doi: 10.1007/s11910-023-01316-9
pii: 10.1007/s11910-023-01316-9
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2023. The Author(s).

Auteurs

Kasey Jackson (K)

Brain Tumor Institute, Children's National Hospital, Washington D C, USA. kej2m@virginia.edu.
Division of Hematology and Oncology, Children's National Hospital, Washington D C, USA. kej2m@virginia.edu.

Roger J Packer (RJ)

Brain Tumor Institute, Children's National Hospital, Washington D C, USA.
Center for Neuroscience and Behavioral Medicine, Children's National Hospital, Washington D C, USA.

Classifications MeSH